Non-Hodgkin Lymphoma

Elizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

The heterogeneity of mantle cell lymphoma will require new combination strategies to improve outcomes.

Lack of improvement in failure-free survival for patients with follicular lymphoma has fueled interest in new treatment strategies that might offer promise of better outcomes.

Patients with follicular lymphoma progressing within 2 years on first-line R-CHOP have a 5-year overall survival rate of only 50%, compared with 90% in longer responders.

The anti-CD20 agent obinutuzumab improved overall response and had acceptable toxicity compared with rituximab in patients with relapsed indolent non-Hodgkin Lymphoma, according to the final results from the GAUSS study.

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses the phase III SELENE study, which is examining the addition of ibrutinib to either R-CHOP or bendamustine plus rituximab for the treatment of patients with follicular lymphoma.

Ibrutinib had an overall response rate of 37% in patients with activated B-cell-like diffuse large B-cell lymphoma.

Tahir Latif, MD, discusses results of a recent study which found that men may have a lower rate of survival among patients with diffuse large B-cell lymphoma.

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, discusses the phase III GADOLIN study, which looks at the anti-CD20 agent obinutuzumab (Gazyva) and bendamustine compared with bendamustine alone in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).